Genmab (GMAB) Stock Highlights

20.31 | +1.1%

2024-12-21 00:50:26

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmabs proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmabs leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered wth Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Statistics

Range Today

20.13 20.43

Volume Today 1.82M

Range 1 Year

19.85 32.88

Volume 1 Year 185.35M

Range 3 Year

19.85 47.5

Volume 3 Year 488.67M

Range 10 Year

4.4 103.19

Volume 10 Year 846.25M

Highlights

Market Capitalization 14.66B (large)

Floating Shares 62.84M

Current Price 20.31

Price To Earnings 21.98

Price To Revenue -0.75

Price To Book 0.05

Earnings Per Share 1.04

Payout Ratio 0%

Performance

Latest +1.1%

1 Month -0.88%

3 Months -21.64%

6 Months -20.94%

1 Year -34.86%

3 Years -46.96%

5 Years -6.79%

10 Years +239.75%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.